![]() |
Name |
Nigrosporin
|
Molecular Formula | C16H16O6 | |
IUPAC Name* |
6,7,10-trihydroxy-2-methoxy-7-methyl-6,8-dihydro-5H-anthracene-1,4-dione
|
|
SMILES |
COC1=CC(=O)c2c(cc3c(c2O)CC(O)C(C)(O)C3)C1=O
|
|
InChI |
InChI=1S/C16H16O6/c1-16(21)6-7-3-9-13(15(20)8(7)4-12(16)18)10(17)5-11(22-2)14(9)19/h3,5,12,18,20-21H,4,6H2,1-2H3/t12-,16+/m1/s1
|
|
InChIKey |
QNFWEYHUDXOXHJ-WBMJQRKESA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 304.3 | ALogp: | 0.5 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.1 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.712 |
Caco-2 Permeability: | -5.105 | MDCK Permeability: | 0.00000833 |
Pgp-inhibitor: | 0.02 | Pgp-substrate: | 0.984 |
Human Intestinal Absorption (HIA): | 0.122 | 20% Bioavailability (F20%): | 0.802 |
30% Bioavailability (F30%): | 0.054 |
Blood-Brain-Barrier Penetration (BBB): | 0.015 | Plasma Protein Binding (PPB): | 93.04% |
Volume Distribution (VD): | 0.572 | Fu: | 10.30% |
CYP1A2-inhibitor: | 0.493 | CYP1A2-substrate: | 0.877 |
CYP2C19-inhibitor: | 0.024 | CYP2C19-substrate: | 0.211 |
CYP2C9-inhibitor: | 0.141 | CYP2C9-substrate: | 0.604 |
CYP2D6-inhibitor: | 0.054 | CYP2D6-substrate: | 0.226 |
CYP3A4-inhibitor: | 0.129 | CYP3A4-substrate: | 0.239 |
Clearance (CL): | 16.003 | Half-life (T1/2): | 0.918 |
hERG Blockers: | 0.026 | Human Hepatotoxicity (H-HT): | 0.188 |
Drug-inuced Liver Injury (DILI): | 0.756 | AMES Toxicity: | 0.594 |
Rat Oral Acute Toxicity: | 0.136 | Maximum Recommended Daily Dose: | 0.132 |
Skin Sensitization: | 0.903 | Carcinogencity: | 0.03 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.622 |
Respiratory Toxicity: | 0.234 |